Top ▲
GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).
The H+/K+ ATPase is a heterodimeric protein, made up of α and β subunits. The α subunit has 10 TM domains and exhibits catalytic and pore functions, while the β subunit has a single TM domain, which appears to be required for intracellular trafficking and stabilising the α subunit. The ATP4A and ATP4B subunits are expressed together, while the ATP12A subunit is suggested to be expressed with the β1 (ATP1B1) subunit of the Na+/K+-ATPase [1].
ATP12A Show summary »
|
||||||||||||||||
ATP4B Show summary » |
Database page citation:
H+/K+-ATPases. Accessed on 30/06/2025. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=160.
Concise Guide to PHARMACOLOGY citation:
Alexander SPH, Fabbro D, Kelly E, Mathie AA, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Davies JA et al. (2023) The Concise Guide to PHARMACOLOGY 2023/24: Transporters. Br J Pharmacol. 180 Suppl 2:S374-469.
The gastric H+/K+-ATPase is inhibited by proton pump inhibitors (PPIs, e.g. dexlansoprazole and esomeprazole) which are used to treat excessive gastric acid secretion. PPIs have a gradual onset of action. More quickly acting potassium-competitive acid blockers (P-CABs; e.g. vonoprazan, revaprazan and tegoprazan) have now entered the clinic. P-CABs are competitive and reversible H+/K+ ATPase blockers and their effect on acid suppression is stronger and more sustained compared to PPIs.